Cargando…

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas

Background: Patients with advanced soft tissue sarcomas (STS) have a dismal prognosis with few effective therapeutic options. A defect in the homologous recombination repair (HRR) pathway can accumulate DNA repair errors and gene mutations, which can lead to tumorigenesis. BRCAness describes tumors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hongyi, Tu, Jian, Zhao, Zhiqiang, Chen, Lijuan, Qu, Yueting, Li, Hongbo, Yao, Hao, Wang, Xiaoshuai, Lee, Dung-Fang, Shen, Jingnan, Wen, Lili, Huang, Gang, Xie, Xianbiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449912/ https://www.ncbi.nlm.nih.gov/pubmed/32863940 http://dx.doi.org/10.7150/thno.45763

Ejemplares similares

Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness
por: Thompson, Timothy C., et al.
Publicado: (2017)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
por: Xavier, Mary-Ann, et al.
Publicado: (2021)

Development of a novel BRCAness score that predicts response to PARP inhibitors
por: Oshi, Masanori, et al.
Publicado: (2022)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma
por: Liu, Qi, et al.
Publicado: (2021)

BRCAness in prostate cancer
por: Bednarz-Knoll, Natalia, et al.
Publicado: (2019)

The BRCAness Landscape of Cancer
por: Guo, Maoni, et al.
Publicado: (2022)

A case of niraparib PARP-Inhibitor induced Sweet Syndrome in gynecologic cancer
por: Badiner, Nora, et al.
Publicado: (2023)

Comparison between low-dose chemotherapy and surgery for the treatment of extremity-associated solitary bone lesions in children with Langerhans cell histiocytosis in South China: A case-control study
por: Li, Hongyi, et al.
Publicado: (2018)

AURKA inhibition mimics BRCAness
por: Hirst, Jeff, et al.
Publicado: (2017)

DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma
por: Barenboim, Maxim, et al.
Publicado: (2021)

The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
por: Shen, Hong-Yuan, et al.
Publicado: (2022)

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
por: Bonciarelli, Stefano, et al.
Publicado: (2023)

Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness
por: Darbeheshti, Farzaneh, et al.
Publicado: (2022)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Niraparib for ovarian cancer
Publicado: (2021)

Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status
por: Genther Williams, Sybil M, et al.
Publicado: (2015)

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
por: Sun, Kaiming, et al.
Publicado: (2018)

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
por: Ha, Kyungsoo, et al.
Publicado: (2014)

Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts
por: Póti, Ádám, et al.
Publicado: (2018)

BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence
por: Wysham, Weiya Z., et al.
Publicado: (2012)

Identification of driver genes associated with chemotherapy resistance of Ewing’s sarcoma
por: Liao, Hongyi, et al.
Publicado: (2018)

The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
por: Morra, Francesco, et al.
Publicado: (2022)

BRCAness as a prognostic indicator in patients with early breast cancer
por: Liu, Lei, et al.
Publicado: (2020)

Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge
por: Caeiro, Cláudia, et al.
Publicado: (2022)

Plastic lengthening amputation with vascularized bone grafts in children with bone sarcoma: a preliminary report
por: Zhao, Zhiqiang, et al.
Publicado: (2020)

Comparison of local control and survival outcomes between surgical and non-surgical local therapy on pelvic Ewing’s sarcoma patients: a meta-analysis
por: Xie, Xianbiao, et al.
Publicado: (2020)

Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
por: van Andel, Lotte, et al.
Publicado: (2017)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers
por: Sisay, Mekonnen, et al.
Publicado: (2017)

Long-term outcomes of limb salvage treatment with custom-made extendible endoprosthesis for bone sarcoma around the knee in children
por: Zou, Changye, et al.
Publicado: (2020)

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness
por: Tutt, A
Publicado: (2018)

Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer
por: Lin, Po‐Han, et al.
Publicado: (2020)

Survival-associated alternative splicing signatures in soft tissue sarcomas
por: Ren, Xianghai, et al.
Publicado: (2020)

Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
por: O’Brien, Shane, et al.
Publicado: (2023)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
por: Holme, Harriett, et al.
Publicado: (2018)

Development of a radiosensitivity gene signature for patients with soft tissue sarcoma
por: Tang, Zaixiang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9e6fp7pelmgogdm5ncv6e5lpul